biotech · Esophageal Squamous Cell Carcinoma
Jiangsu Alphamab Biopharmaceuticals
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Jiangsu Alphamab Biopharmaceuticals is a biotech organization headquartered in CN. Primary therapeutic focus areas include Esophageal Squamous Cell Carcinoma. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s)
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
KN046
Phase 2 · small molecule · Esophageal Squamous Cell Carcinoma
KN046 for Esophageal Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Jiangsu Alphamab Biopharmaceuticals Co., Ltd with 1 ClinicalTrials.gov record(s).
Internal code KN046-204
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Esophageal Squamous Cell Carcinoma
- Status
- completed
- Trials
- 1